Avelumab (anti-PD-L1)

Cat. No.: HY-108730A Purity: 97.44%: Data Sheet
COA

SDS

FAQs
Technical Support

Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma.

For research use only. We do not sell to patients.

CAS No. : 1537032-82-8

Size	Stock	Quantity
Free Sample (100 μg)	Apply Now
Free Sample (100 μg)	Apply Now
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 10 publication(s) in Google Scholar

Other Forms of Avelumab (anti-PD-L1):

Avelumab In-stock

10 Publications Citing Use of MCE Avelumab (anti-PD-L1)

Bio/Physico-chemical Assay

Flow Cytometry

In Vivo Efficacy Study

IHC

Cell Imaging/Staining

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]; Regardless of whether it was PANC-1 or PAN02 cells, the PD-L1-targeting effect of NGHP was comparable to that of the αPD-L1 (Avelumab, 1 μg/mL, 1 h), with the PD-L1 expression distribution exhibiting a rightward shift.

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]; Due to the relatively low PD-L1 expression on conventional PANC-1 cells, less avelumab was bound, leading to moderate toxicity of about 7.5% cell lysis rate for simple antibody and NGHP. While in PANC-1 cells with PD-L1 up-regulation induced by radiation, the ADCC-induced cell lysis rate increased.

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]; Schematic of RT (6 Gy at day 1 and day 3), PFD (10 mg/kg), HAase (6.5 mg/kg), and αPD-L1 (avelumab; 12 mg/kg) were used via intravenous (iv) injection from day 1 to day 9 (qod) in PAN02 cells/mPSCs bearing mice. Represent images of excised tumors after different treatments.

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]; Schematic of RT (6 Gy at day 1 and day 3), PFD (10 mg/kg), HAase (6.5 mg/kg), and αPD-L1 (avelumab; 12 mg/kg) were used via intravenous (iv) injection from day 1 to day 9 (qod) in PAN02 cells/mPSCs bearing mice. Immunohistochemistry evaluation for α-SMA of PAN02&mPSC tumors obtained from C57BL/6 mice.

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Jun 14:102195. [Abstract]; To demonstrate that MICA/B CAR⁺hnCD16⁺ iT cells are capable of flexibly utilizing antibodies to supplement CAR efficacy, MICA/B CAR⁺hnCD16⁺ iT cells were co-cultured with the MICA/B^HighEGFR⁺PDL1⁺HER2⁺ CaSki tumor cell line and individually supplemented with different therapeutic antibodies: Cetuximab targeting EGFR, Avelumab against PDL1, and Herceptin for HER2.

: Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Mar 15;8(1):107. [Abstract]; Co-culture of A2058 cells transfected with control or SIRT7 overexpression plasmid with TG treatment and activated T cells (1:3) for 24 h with or without the treatment with PD-L1 neutralizing antibody (Avelumab, 20 μg/mL) for 8 h. Cytotoxicity was then quantified by a spectrometer at OD (570 nm) followed by crystal violet staining.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Avelumab (anti-PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab (anti-PD-L1) enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab (anti-PD-L1) can be used for the study of chordoma^[1].
Isotype	Human IgG1 lambda
Recommend Isotype Controls	Human IgG1 lambda1, Isotype Control
Species Reactivity	Human
IC₅₀ & Target	B7-H1/PD-L1/CD274
In Vitro	Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity property. Avelumab increases NK-cell lysis 3.1-fold in JHC7 cells relative to isotype control. When the cells are treated with IFN-γ, Avelumab markedly enhances NK-cell lysis relative to isotype control in the following cell lines: JHC7 (7.56-fold), UM-Chor1 (7.34-fold), U-CH2 (2.6 fold), MUG-Chor1 (8.38-fold). Avelumab effectively increases antibody-dependent cell-mediated cytotoxicity (ADCC) of both the non-cancer stem cell (CSC) and CSC subpopulations to the same degree^[1]. Results also demonstrate that the addition of Avelumab increases the frequency of antigen-specific multifunctional CD8⁺ T cells by more than fivefold, relative to the isotype control in CEFT-stimulated peripheral blood mononuclear cells (PBMCs)^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Avelumab (anti-PD-L1) Related Antibodies
In Vivo	Measurement of individual tumors clearly shows a slowing of tumor growth in the Avelumab-treated mice. By day 36 post-tumor implantation, there is a significant (P<0.01) reduction in the average tumor volume of the Avelumab-treated mice. Reduction in MB49 tumor growth in the mice treated with Avelumab is durable and leads to a significant (P<0.05) improvement in percent survival. Avelumab treatment of 10 mice with bladder tumors results in complete tumor regression in 8 mice, confirmed by histopathology. However, in mice depleted of either CD4 or CD8 cells, Avelumab treatment is much less effective in controlling bladder tumor burden with tumor breakthrough occurring in a higher frequency in mice depleted of CD4 T cells^[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID	29126 [NCBI]
Accession	Q9NZQ7
Application	ELISA, FACS, Functional assay
Conjugated	Unconjugated
Reconsititution	The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight	150 kDa
CAS No.	1537032-82-8
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Avelumab (anti-PD-L1)]
Shipping	Shipping with dry ice.
Formulation	Please refer to the lot-specific COA for specific buffer information.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Format	Human IgG1 lambda1
Biological Activity	Avelumab has a significant ADCC effect on HEK293/PD-L1 cells in a dose-dependent manner.The EC₅₀ for this effect is 12.64 and 13.49 ng/mL.
Purity & Documentation	Purity: 97.44% Select Batch: Data Sheet (262 KB) SDS (251 KB) COA (232 KB) SDS-PAGE (62 KB) SEC-HPLC (124 KB) Inhibitory Antibodies User Guide (603 KB)
References	[1]. Fujii R, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. 2016 Jun 7;7(23):33498-511. [Content Brief] [2]. Grenga I, et al. A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. Clin Transl Immunology. 2016 May 20;5(5):e83. [Content Brief] [3]. Vandeveer AJ, et al. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor. Cancer Immunol Res. 2016 May;4(5):452-62. [Content Brief]